Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.2042
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.1873/ 81
  • Ask / Lots
    0.1917/ 5
  • Open / Previous Close
    --- / 0.2042
  • Day Range
    ---
  • 52 Week Range
    0.1180
    22.1376
  • Volume
    391,239

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
TNXP
Tonix Pharmaceuticals Holding Corp
38.2M
0.0x
---
LVTX
LAVA Therapeutics NV
38.9M
-1.6x
---
AFMD
Affimed NV
40.2M
-0.6x
---
DRRX
DURECT Corp
26.8M
-1.6x
---
CRIS
Curis Inc
34.0M
-0.5x
---
BOLT
Bolt Biotherapeutics Inc
21.7M
-0.3x
---
As of 2024-11-22

Company Information

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.

Contact Information

Headquarters
26 Main Street, Suite 101CHATHAM, NJ, United States 07928
Phone
212-980-9155
Fax
212-923-5700

Executives

Chairman of the Board, President, Chief Executive Officer
Seth Lederman
Chief Financial Officer, Treasurer
Bradley Saenger
Chief Operating Officer
Jessica Morris
Chief Medical Officer, Secretary
Gregory Sullivan
Lead Independent Director
James Treco

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$38.2M
Revenue (TTM)
$11.3M
Shares Outstanding
186.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.24
EPS
$-52.81
Book Value
$57.61
P/E Ratio
0.0x
Price/Sales (TTM)
3.4
Price/Cash Flow (TTM)
---
Operating Margin
-1,253.65%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.